Product nameAnti-HIP2 antibody [EP1145Y]
See all HIP2 primary antibodies
DescriptionRabbit monoclonal [EP1145Y] to HIP2
Tested applicationsSuitable for: WB, IP, IHC-P, ICC/IFmore details
Unsuitable for: Flow Cyt
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human HIP2 aa 150-250 (internal sequence). The exact sequence is proprietary.
- Daudi cell lysate or human liver tissue.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol, 0.5% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab52930 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/100000. Detects a band of approximately 24 kDa (predicted molecular weight: 22 kDa).|
|IHC-P||1/250 - 1/500. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.|
FunctionAccepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro, in the presence or in the absence of BRCA1-BARD1 E3 ubiquitin-protein ligase complex, catalyzes the synthesis of 'Lys-48'-linked polyubiquitin chains. Does not transfer ubiquitin directly to but elongates monoubiquitinated substrate protein. Mediates the selective degradation of short-lived and abnormal proteins, such as the endoplasmic reticulum-associated degradation (ERAD) of misfolded lumenal proteins. Ubiquitinates huntingtin. May mediate foam cell formation by the suppression of apoptosis of lipid-bearing macrophages through ubiquitination and subsequence degradation of p53/TP53. Proposed to be involved in ubiquitination and proteolytic processing of NF-kappa-B; in vitro supports ubiquitination of NFKB1. In case of infection by cytomegaloviruses may be involved in the US11-dependent degradation of MHC class I heavy chains following their export from the ER to the cytosol. In case of viral infections may be involved in the HPV E7 protein-dependent degradation of RB1.
Tissue specificityExpressed in all tissues tested, including spleen, thymus, prostate, testis, ovary, small intestine, colon, peripheral blood leukocytes, T-lymphocytes, monocytes, granulocytes and bone marrow mononuclear cells. Highly expressed in brain, with highest levels found in cortex and striatum and at lower levels in cerebellum and brainstem.
PathwayProtein modification; protein ubiquitination.
Sequence similaritiesBelongs to the ubiquitin-conjugating enzyme family.
Contains 1 UBA domain.
modificationsSumoylation at Lys-14 impairs catalytic activity.
- Information by UniProt
- E2 25K antibody
- E2(25K) antibody
- HIP-2 antibody
Anti-HIP2 antibody [EP1145Y] (ab52930) at 1/100000 dilution + Daudi cell lysate at 10 µg
Goat anti-Rabbit HRP labeled at 1/2000 dilution
Predicted band size: 22 kDa
Observed band size: 24 kDa why is the actual band size different from the predicted?
Ab52930 (1:250) staining human HIP2 in human liver tissue by immunohistochemistry using paraffin embedded tissue.
This product has been referenced in:
- McManus FP et al. Quantitative SUMO proteomics reveals the modulation of several PML nuclear body associated proteins and an anti-senescence function of UBC9. Sci Rep 8:7754 (2018). Read more (PubMed: 29773808) »
- Benedikt A et al. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia 25:135-44 (2011). WB ; Human . Read more (PubMed: 21030982) »